Pub Date : 2021-08-10DOI: 10.31487/j.cor.2021.08.02
R. S. Hamad, N. K. A. Abdulsalam, A. Mashaal, R. El-Araby
Hepatocellular carcinoma (HCC) remains the main type of liver cancer. Understanding the molecular and immune mechanisms of HCC tumorigenesis are required to develop effective biomarkers. This study is designed to measure the circulating MMP9 and CEBPα to provide a diagnostic and prognostic biomarker for HCV-genotype (4) induced liver cirrhosis and carcinogenesis. This study included one hundred Egyptian patients, divided into two groups 50 patients each. The first group: classified into Chronic Liver Disease (CLD) without cirrhosis (n=25) and CLD with cirrhosis (n=25). The second group: classified into CLD patients with HCC, (n=25), and healthy control (25 volunteers). The expression of MMP9 and CEBPα genes were analysed using Real-Time PCR. Our results showed significant downregulation in MMP9 and CEBPα genes in cirrhotic and HCC patients (p< 0.001 and p<0.001) respectively. There was a significant (p< 0.001) diagnostic capacity between HCC patients against CLD with or without cirrhosis patients. Bioinformatics analysis revealed a relationship between MMP9 and CEBPα genes. In conclusion, the gradual decrease in the expression of MMP9 and CEBPα gene during the progression of the disease recommended use of MMP9 and CEBPα genes as a diagnostic and prognostic biomarker for both cirrhosis and HCC in HCV-genotype (4) patients.
{"title":"MMP9 and CEBPα Genes as a New Prognostic Biomarker for Hepatocellular Carcinoma Caused by Infection with HCV-Genotype (4)","authors":"R. S. Hamad, N. K. A. Abdulsalam, A. Mashaal, R. El-Araby","doi":"10.31487/j.cor.2021.08.02","DOIUrl":"https://doi.org/10.31487/j.cor.2021.08.02","url":null,"abstract":"Hepatocellular carcinoma (HCC) remains the main type of liver cancer. Understanding the molecular and immune mechanisms of HCC tumorigenesis are required to develop effective biomarkers. This study is designed to measure the circulating MMP9 and CEBPα to provide a diagnostic and prognostic biomarker for HCV-genotype (4) induced liver cirrhosis and carcinogenesis. This study included one hundred Egyptian patients, divided into two groups 50 patients each. The first group: classified into Chronic Liver Disease (CLD) without cirrhosis (n=25) and CLD with cirrhosis (n=25). The second group: classified into CLD patients with HCC, (n=25), and healthy control (25 volunteers). The expression of MMP9 and CEBPα genes were analysed using Real-Time PCR. Our results showed significant downregulation in MMP9 and CEBPα genes in cirrhotic and HCC patients (p< 0.001 and p<0.001) respectively. There was a significant (p< 0.001) diagnostic capacity between HCC patients against CLD with or without cirrhosis patients. Bioinformatics analysis revealed a relationship between MMP9 and CEBPα genes. In conclusion, the gradual decrease in the expression of MMP9 and CEBPα gene during the progression of the disease recommended use of MMP9 and CEBPα genes as a diagnostic and prognostic biomarker for both cirrhosis and HCC in HCV-genotype (4) patients.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78485716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-02DOI: 10.31487/j.cor.2021.08.01
A. Patané, C. Poleri, L. Vila, Basile Florencia, Guman Gabriela, Raya Mercedes, Rivero Hector, Rosales Adolfo, Rosenberg Moises
Background: Thymomas are a heterogeneous group of tumors which represent the most frequent tumor of the anterior mediastinum. Aims: To describe the clinical, histological, surgical and oncological characteristics of a cohort of patients with a diagnosis of thymoma surgically treated in two centers in Argentina and to evaluate the possibility of retrospectively implementing the 8th edition of TNM staging. Materials and Methods: 180 patients with thymoma surgically treated over a period of 41 years were studied. The following variables were analysed: age, sex, presence of myasthenia gravis at diagnosis, Masaoka staging (1994), TNM staging of thymus tumors, Histological classification (WHO 2015), neoadjuvant treatment with chemotherapy, post-operative radiation treatment and clinical evolution of myasthenia gravis defined according to the modified Osserman classification. Results: 96 men and 84 women were analysed. Median age 51 years (range 13-85). 85% of the patients analysed came from the public sphere. When analysing the institutional distribution by Masaoaka-Koga stage and TNM, a higher proportion of stages I was observed for both staging systems. Most myasthenic patients belonged to the WHO B2 histological classification (49%, p=0.04) and 15 patients received neoadjuvant treatment prior to surgery to improve the chances of resection, most of them classified as stages III of Masaoka (p=0.002) or IIIa of the TNM stage (p=0.001). 74 (46%) cases received post-operative RT when they presented Masaoka Koga stages II (p=0.000) and IIIa or more advanced TNM staging (p=0.000). 76% of the patients presented remission or stability of symptoms after surgical treatment and only 3/6 died due to myasthenic crisis in the immediate post-operative period. Conclusion: As reported in the literature, we have observed a higher frequency of B2 thymomas and their association with Myasthenia gravis. The histological criteria of the WHO 2015 classification, based on the ITMIG recommendations, favour precision in the definition of subtypes. The retrospective implementation of the 8th edition of TNM staging highlights the need to standardize protocols for pathological and surgical studies.
{"title":"Thymomas: Analysis of Histological Subtypes and Staging in Patients with Surgical Treatment in Two Reference Centers in Argentina","authors":"A. Patané, C. Poleri, L. Vila, Basile Florencia, Guman Gabriela, Raya Mercedes, Rivero Hector, Rosales Adolfo, Rosenberg Moises","doi":"10.31487/j.cor.2021.08.01","DOIUrl":"https://doi.org/10.31487/j.cor.2021.08.01","url":null,"abstract":"Background: Thymomas are a heterogeneous group of tumors which represent the most frequent tumor of \u0000the anterior mediastinum. \u0000Aims: To describe the clinical, histological, surgical and oncological characteristics of a cohort of patients \u0000with a diagnosis of thymoma surgically treated in two centers in Argentina and to evaluate the possibility \u0000of retrospectively implementing the 8th edition of TNM staging. \u0000Materials and Methods: 180 patients with thymoma surgically treated over a period of 41 years were \u0000studied. The following variables were analysed: age, sex, presence of myasthenia gravis at diagnosis, \u0000Masaoka staging (1994), TNM staging of thymus tumors, Histological classification (WHO 2015), \u0000neoadjuvant treatment with chemotherapy, post-operative radiation treatment and clinical evolution of \u0000myasthenia gravis defined according to the modified Osserman classification. \u0000Results: 96 men and 84 women were analysed. Median age 51 years (range 13-85). 85% of the patients \u0000analysed came from the public sphere. When analysing the institutional distribution by Masaoaka-Koga \u0000stage and TNM, a higher proportion of stages I was observed for both staging systems. Most myasthenic \u0000patients belonged to the WHO B2 histological classification (49%, p=0.04) and 15 patients received \u0000neoadjuvant treatment prior to surgery to improve the chances of resection, most of them classified as stages \u0000III of Masaoka (p=0.002) or IIIa of the TNM stage (p=0.001). 74 (46%) cases received post-operative RT \u0000when they presented Masaoka Koga stages II (p=0.000) and IIIa or more advanced TNM staging (p=0.000). \u000076% of the patients presented remission or stability of symptoms after surgical treatment and only 3/6 died \u0000due to myasthenic crisis in the immediate post-operative period. \u0000Conclusion: As reported in the literature, we have observed a higher frequency of B2 thymomas and their \u0000association with Myasthenia gravis. The histological criteria of the WHO 2015 classification, based on the \u0000ITMIG recommendations, favour precision in the definition of subtypes. The retrospective implementation \u0000of the 8th edition of TNM staging highlights the need to standardize protocols for pathological and surgical \u0000studies.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85179103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-30DOI: 10.31487/j.cor.2021.06.02
S. Pareek, U. Jain, Mayukh Tikadar, Prabhanshu Kumar, R. Pudake, N. Chauhan
Cervical cancer has the highest mortality rate worldwide. In the quest for reducing such a high mortality rate, advancements in diagnosis as well as treatment are being undertaken at various scales across the globe. With the recent advancements in the applications of nanotechnology, simple, rapid and inexpensive diagnostic methods for cervical cancer, i.e., human papillomavirus (HPV), especially high-risk oncogenic subtypes 16 and 18 have started to gain attention of health care practitioners. This review outlines the current applications of biosensors for the diagnosis of HPV, as compared to the conventional techniques for measuring HPV that have some limitations. The traditional methods used for cervix cancer are less sensitive, whereas nanotechnology has greatly improved the sensitivity. Due to cancer incidence and mortality growing rapidly worldwide, the prevalence and risk factors are also discussed in this review.
{"title":"Advancements and Future Predictions on Diagnostic Approaches towards Cervical Cancer through Nanotechnology-Based Sensors for the Detection of Human Papillomavirus","authors":"S. Pareek, U. Jain, Mayukh Tikadar, Prabhanshu Kumar, R. Pudake, N. Chauhan","doi":"10.31487/j.cor.2021.06.02","DOIUrl":"https://doi.org/10.31487/j.cor.2021.06.02","url":null,"abstract":"Cervical cancer has the highest mortality rate worldwide. In the quest for reducing such a high mortality \u0000rate, advancements in diagnosis as well as treatment are being undertaken at various scales across the globe. \u0000With the recent advancements in the applications of nanotechnology, simple, rapid and inexpensive \u0000diagnostic methods for cervical cancer, i.e., human papillomavirus (HPV), especially high-risk oncogenic \u0000subtypes 16 and 18 have started to gain attention of health care practitioners. This review outlines the current \u0000applications of biosensors for the diagnosis of HPV, as compared to the conventional techniques for \u0000measuring HPV that have some limitations. The traditional methods used for cervix cancer are less sensitive, \u0000whereas nanotechnology has greatly improved the sensitivity. Due to cancer incidence and mortality \u0000growing rapidly worldwide, the prevalence and risk factors are also discussed in this review.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72698049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-28DOI: 10.31487/j.cor.2021.07.05
N. Dassi, N. S. Silva, F. Silva, D. Almeida, M.R. Oliveira, S. Cavalheiro, P. Dastoli, M. D. Seixas, A. Cappellano
Purpose: The vinca alkaloids’ activity against pediatric low-grade glioma (PLGG) is well established. The goal of the present study is to describe our experience with oral vinorelbine in patients with progressive optic pathway glioma (OPG), not only regarding the clinical response, but also the cost benefit using an oral medication. Methods: Patients under 21 years of age with unresectable and/or progressive OPG were eligible. Oral vinorelbine was administered at a dose of 90mg/m2 daily on days 0, 8 and 22, in a scheme of 4 weekly cycles for a total of 18 cycles (54 doses). Results: From 2013 to 2018, sixteen patients were enrolled onto the study, with a median age of 9,1 years (range 4,6-17,8y). The most common histology was pilocytic astrocytoma (88,8%). Best response to chemotherapy was reviewed with a response rate (complete, partial, or minor response) of 30% for the patients treated exclusively with the oral drug. Five-year event-free survival (EFS) rate was 43.4%. Six patients had to change to intravenous vinorelbine due to gastrointestinal toxicity, vomiting grade III. None of the patients showed neurotoxicity. The total cost including drug acquisition, administration and toxicity management was lower with the oral formulation comparing to IV one. Conclusion: Single-agent oral vinorelbine seems to have some clinical activity in the management of recurrent or refractory pediatric OPG, being an interesting and cost-effective option, minding that gastrointestinal toxicity may be limiting and a combination of antiemetics should be considered in this treatment regimen.
{"title":"Single-Agent Oral Vinorelbine in the Treatment of Pediatric Progressive Optic Pathway Glioma: A Single Institutional Experience","authors":"N. Dassi, N. S. Silva, F. Silva, D. Almeida, M.R. Oliveira, S. Cavalheiro, P. Dastoli, M. D. Seixas, A. Cappellano","doi":"10.31487/j.cor.2021.07.05","DOIUrl":"https://doi.org/10.31487/j.cor.2021.07.05","url":null,"abstract":"Purpose: The vinca alkaloids’ activity against pediatric low-grade glioma (PLGG) is well established. The \u0000goal of the present study is to describe our experience with oral vinorelbine in patients with progressive \u0000optic pathway glioma (OPG), not only regarding the clinical response, but also the cost benefit using an oral \u0000medication. Methods: Patients under 21 years of age with unresectable and/or progressive OPG were \u0000eligible. Oral vinorelbine was administered at a dose of 90mg/m2 daily on days 0, 8 and 22, in a scheme of \u00004 weekly cycles for a total of 18 cycles (54 doses). \u0000Results: From 2013 to 2018, sixteen patients were enrolled onto the study, with a median age of 9,1 years \u0000(range 4,6-17,8y). The most common histology was pilocytic astrocytoma (88,8%). Best response to \u0000chemotherapy was reviewed with a response rate (complete, partial, or minor response) of 30% for the \u0000patients treated exclusively with the oral drug. Five-year event-free survival (EFS) rate was 43.4%. Six \u0000patients had to change to intravenous vinorelbine due to gastrointestinal toxicity, vomiting grade III. None \u0000of the patients showed neurotoxicity. The total cost including drug acquisition, administration and toxicity \u0000management was lower with the oral formulation comparing to IV one. \u0000Conclusion: Single-agent oral vinorelbine seems to have some clinical activity in the management of \u0000recurrent or refractory pediatric OPG, being an interesting and cost-effective option, minding that \u0000gastrointestinal toxicity may be limiting and a combination of antiemetics should be considered in this \u0000treatment regimen.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81796996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.31487/j.cor.2021.07.04
B. D. Rauglaudre, E. Norguet-Monnereau, M. Duluc, I. Nanni, J. Mancini, L. Dahan
Introduction: Tumor-based molecular profiling has increased in the area of precision medicine. Their routine use is still limited by accessibility, cost and availability of tumor material. Materials and Methods: We retrospectively analysed the treatment received and the survival data of patients with digestive cancer who received molecular high-throughput sequencing (NGS) analyses at diagnosis. The primary objective of this single-center study was to compare the overall survival of patients who were treated with molecularly matched therapy with patients who received standard therapy. Median overall survival was calculated from initial disease diagnosis to death. Results: 528 patients were referred to the Digestive Oncology Department of the Timone Hospital in Marseille between January 2018, and November 2020 for management of digestive cancer and received high-throughput molecular sequencing. Among them, 461 patients had a digestive carcinoma (75 of them were excluded because of the presence of a GIST or a neuroendocrine tumor, a digestive localization of extra digestive cancer or the absence of follow-up in our center) and 275 had metastatic disease (synchronous or metachronous). For metastatic patients, actionable molecular alterations were identified in95 patients (43.5%) and for 13 patients (4.7%) a molecularly matched therapy was administered. There was no significant difference in median overall survival between patients who received matched therapy than patients who did not receive molecularly matched therapy (2.89 [95%CI 1.84 - 3.93] vs. 2.86 [95%CI 1.52 - 4.19], p=0.671). Conclusion: This study suggests that high-throughput genomics can improve management of patients. Although these results did not show a benefit in overall survival for tumors who harboured such actionable molecular alterations and who received molecularly matched therapy, than patients who did not receive molecularly matched therapy, they are promising. Randomized trials are needed to confirm that there is a benefit to treating patients with matched therapy based on NGS.
{"title":"Impact of a Molecular Sequencing Systematic at Diagnosis in Digestive Oncology: Experience of a French Center","authors":"B. D. Rauglaudre, E. Norguet-Monnereau, M. Duluc, I. Nanni, J. Mancini, L. Dahan","doi":"10.31487/j.cor.2021.07.04","DOIUrl":"https://doi.org/10.31487/j.cor.2021.07.04","url":null,"abstract":"Introduction: Tumor-based molecular profiling has increased in the area of precision medicine. Their routine use is still limited by accessibility, cost and availability of tumor material.\u0000Materials and Methods: We retrospectively analysed the treatment received and the survival data of patients with digestive cancer who received molecular high-throughput sequencing (NGS) analyses at diagnosis. The primary objective of this single-center study was to compare the overall survival of patients who were treated with molecularly matched therapy with patients who received standard therapy. Median overall survival was calculated from initial disease diagnosis to death.\u0000Results: 528 patients were referred to the Digestive Oncology Department of the Timone Hospital in Marseille between January 2018, and November 2020 for management of digestive cancer and received high-throughput molecular sequencing. Among them, 461 patients had a digestive carcinoma (75 of them were excluded because of the presence of a GIST or a neuroendocrine tumor, a digestive localization of extra digestive cancer or the absence of follow-up in our center) and 275 had metastatic disease (synchronous or metachronous). For metastatic patients, actionable molecular alterations were identified in95 patients (43.5%) and for 13 patients (4.7%) a molecularly matched therapy was administered. There was no significant difference in median overall survival between patients who received matched therapy than patients who did not receive molecularly matched therapy (2.89 [95%CI 1.84 - 3.93] vs. 2.86 [95%CI 1.52 - 4.19], p=0.671). \u0000Conclusion: This study suggests that high-throughput genomics can improve management of patients. Although these results did not show a benefit in overall survival for tumors who harboured such actionable molecular alterations and who received molecularly matched therapy, than patients who did not receive molecularly matched therapy, they are promising. Randomized trials are needed to confirm that there is a benefit to treating patients with matched therapy based on NGS.\u0000","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"186 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80630888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-13DOI: 10.31487/J.COR.2021.07.03
A. Rasheed, B. Malik, Narjis Muzaffar, Aneeta Vallecha, S. Sattar, Noor Ul-ain, Najeeb Naimatullah
Introduction: Cancer patients are prone to infections, including COVID-19 because they are immune-comprised secondary to cancer itself as well as due to their treatment. As a principal health care provider, it is imperative that their awareness and practices should be assessed and rectified in a timely manner. Methodology & Results: This is a cross sectional and prospective study, performed in the Oncology OPD of SIUT, Pakistan. Total 306 participants were included. Average percentage of awareness was 39.4% vs 36.6% were found to be low, but patient (72.7%) showed more careful behaviour then their care taker (61.5%). In query related to use of face mask every time while being outside the house, 14.4% vs 23.8% did not practice it. For hand hygiene, 93.4% vs 49.1% were following these measures. Reasons for not following these precautions were: i) lack of information, 63% vs 37% ii) this virus is not lethal, 37% vs 63%. Conclusion: Awareness and practical implementation of knowledge is not according to international guidelines and there is a dire need to have a proper awareness campaign for the masses to improve the acceptability of Corona virus as a major health risk concern.
{"title":"COVID-19 Infection – Awareness and Practices of Cancer Patients and Their Attendants: An Experience from Pakistan","authors":"A. Rasheed, B. Malik, Narjis Muzaffar, Aneeta Vallecha, S. Sattar, Noor Ul-ain, Najeeb Naimatullah","doi":"10.31487/J.COR.2021.07.03","DOIUrl":"https://doi.org/10.31487/J.COR.2021.07.03","url":null,"abstract":"Introduction: Cancer patients are prone to infections, including COVID-19 because they are immune-comprised secondary to cancer itself as well as due to their treatment. As a principal health care provider, it is imperative that their awareness and practices should be assessed and rectified in a timely manner.\u0000Methodology & Results: This is a cross sectional and prospective study, performed in the Oncology OPD of SIUT, Pakistan. Total 306 participants were included. Average percentage of awareness was 39.4% vs 36.6% were found to be low, but patient (72.7%) showed more careful behaviour then their care taker (61.5%). In query related to use of face mask every time while being outside the house, 14.4% vs 23.8% did not practice it. For hand hygiene, 93.4% vs 49.1% were following these measures. Reasons for not following these precautions were: i) lack of information, 63% vs 37% ii) this virus is not lethal, 37% vs 63%.\u0000Conclusion: Awareness and practical implementation of knowledge is not according to international guidelines and there is a dire need to have a proper awareness campaign for the masses to improve the acceptability of Corona virus as a major health risk concern.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83903486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-09DOI: 10.31487/J.COR.2021.07.02
A. Rasheed, Malik Babar, Muzaffar Narjis, Vallecha Aneeta, S. Sattar, Naimatullah Najeeb
Introduction: Cancer patients have concerns about treatment during COVID-19 pandemic virus as well as its impact on their health. This survey was conducted to ascertain perception of cancer patients and their attendants during this pandemic. Methods & Results: This cross-sectional study was conducted at Oncology OPD of SIUT, from May 2020 to July 2020 on cancer patients along with their attendants. Among 306 patients, 68.9% received chemotherapy. In response of each question, 1st one belonged to patients and 2nd was related to attendants. Only positive answers are reported here. For increasing gap of chemotherapy during the pandemic COVID-19, 58.3% vs 38.4% agreed with doctor recommendation. For start of single agent chemotherapy instead of combination regimen, 41% vs 19% agreed. For hospitalization 41.5%, vs 47.7% depicted inclination towards admission whereas for mental health questions, 63.7% vs 51.3% were neither afraid nor had psychological issues 79.7% vs 25.8% respectively. About COVID-19 testing, 66% vs 22.5% wanted to be tested. If results turned out positive, 82.2% vs 24.7% would go in isolation. Conclusion: This study provides evidence of perception of cancer patients with their attendants from resource restrained country. Our study confirms that for disease like cancer, fear of the illness is always more paramount than any infection.
{"title":"Perception of Cancer Patients and Their Attendants during Pandemic of COVID-19: An Experience from Tertiary Care Center, Pakistan","authors":"A. Rasheed, Malik Babar, Muzaffar Narjis, Vallecha Aneeta, S. Sattar, Naimatullah Najeeb","doi":"10.31487/J.COR.2021.07.02","DOIUrl":"https://doi.org/10.31487/J.COR.2021.07.02","url":null,"abstract":"Introduction: Cancer patients have concerns about treatment during COVID-19 pandemic virus as well as \u0000its impact on their health. This survey was conducted to ascertain perception of cancer patients and their \u0000attendants during this pandemic. \u0000Methods & Results: This cross-sectional study was conducted at Oncology OPD of SIUT, from May 2020 \u0000to July 2020 on cancer patients along with their attendants. Among 306 patients, 68.9% received \u0000chemotherapy. In response of each question, 1st one belonged to patients and 2nd was related to attendants. \u0000Only positive answers are reported here. For increasing gap of chemotherapy during the pandemic COVID-19, 58.3% vs 38.4% agreed with doctor recommendation. For start of single agent chemotherapy instead of \u0000combination regimen, 41% vs 19% agreed. For hospitalization 41.5%, vs 47.7% depicted inclination \u0000towards admission whereas for mental health questions, 63.7% vs 51.3% were neither afraid nor had \u0000psychological issues 79.7% vs 25.8% respectively. About COVID-19 testing, 66% vs 22.5% wanted to be \u0000tested. If results turned out positive, 82.2% vs 24.7% would go in isolation.\u0000Conclusion: This study provides evidence of perception of cancer patients with their attendants from \u0000resource restrained country. Our study confirms that for disease like cancer, fear of the illness is always \u0000more paramount than any infection.\u0000","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"199 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91445547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-24DOI: 10.31487/j.cor.2021.06.04
H. Klonoff-Cohen, M. Polavarapu
Purpose: This is the first pilot study to examine survivors’ experiences and primary care physicians and nurse practitioners’ knowledge and behaviour practices with respect to late effects (e.g., fatigue, chemobrain, lymphodema, cardiac problems, reproductive, infertility and sexual health issues, bone problems, and pain). Methods: Two separate focus groups consisting of 5 breast cancer survivors and 5 primary care physicians and nurse practitioners recruited from a local hospital in Central Illinois answered predetermined questions about cancer survivorship care. We intentionally limited the sample in order to conduct a detailed discussion (90 minutes) to gain every participant’s perspective. Results: Breast cancer survivors expressed a void in discussion and lack of knowledge among their primary care physicians regarding late effects as well as psychological consequences, referrals to support groups, and availability of resources (e.g., finances), thereby negatively affecting survivors’ quality of life. A primary care clinician (PCC) focus group revealed a service gap for mental health services for all patients, knowledge deficit about late effects, and lack of awareness of patient resources. Both cancer survivors and PCCs were extremely supportive about a shared care survivorship model between oncology and primary care. All focus group participants were unequivocally receptive about enhancing survivorship care throughout a cancer survivor’s lifetime. Conclusion: Complementing cancer survivorship care with primary care clinicians in the areas of late effects, in addition to psychological consequences, screening, and lifestyle habits will enhance a cancer survivor’s health-related quality of life.
{"title":"Survivorship Care Focus Group Discussions for Breast Cancer Survivors and Primary Care Clinicians","authors":"H. Klonoff-Cohen, M. Polavarapu","doi":"10.31487/j.cor.2021.06.04","DOIUrl":"https://doi.org/10.31487/j.cor.2021.06.04","url":null,"abstract":"Purpose: This is the first pilot study to examine survivors’ experiences and primary care physicians and \u0000nurse practitioners’ knowledge and behaviour practices with respect to late effects (e.g., fatigue, \u0000chemobrain, lymphodema, cardiac problems, reproductive, infertility and sexual health issues, bone \u0000problems, and pain).\u0000Methods: Two separate focus groups consisting of 5 breast cancer survivors and 5 primary care physicians \u0000and nurse practitioners recruited from a local hospital in Central Illinois answered predetermined questions \u0000about cancer survivorship care. We intentionally limited the sample in order to conduct a detailed discussion \u0000(90 minutes) to gain every participant’s perspective.\u0000Results: Breast cancer survivors expressed a void in discussion and lack of knowledge among their primary \u0000care physicians regarding late effects as well as psychological consequences, referrals to support groups, \u0000and availability of resources (e.g., finances), thereby negatively affecting survivors’ quality of life. A \u0000primary care clinician (PCC) focus group revealed a service gap for mental health services for all patients, \u0000knowledge deficit about late effects, and lack of awareness of patient resources. Both cancer survivors and \u0000PCCs were extremely supportive about a shared care survivorship model between oncology and primary \u0000care. All focus group participants were unequivocally receptive about enhancing survivorship care \u0000throughout a cancer survivor’s lifetime.\u0000Conclusion: Complementing cancer survivorship care with primary care clinicians in the areas of late \u0000effects, in addition to psychological consequences, screening, and lifestyle habits will enhance a cancer \u0000survivor’s health-related quality of life.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"137 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73751325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-21DOI: 10.31487/j.cor.2021.06.05
R. Passalacqua, M. Ratti, M. Bonomi, G. Grizzi, F. Negri, F. Crea, M. Giganti, B. Perrucci, M. Brighenti, S. Panni, M. Donini, A. Curti, D. Spada, R. Marchi, G. Donati, J. Saleri, M. Nazzari, G. Pogliacomi, F. Diodati, C. Caminiti
Background: Cancer represents a major risk factor for COVID-19 poor outcomes. During the crucial phase of the pandemic, we launched a home care project, called DomOnCOVID, aiming to provide care to patients in their own homes, enabling to keep immunocompromised individuals away from health care facilities, decrease hospital use, and strengthen hospital capacity for subjects with COVID-19 and other conditions. This paper describes this intervention in terms of feasibility and clinical outcomes. Methods: This is a descriptive study of cancer patients with confirmed or suspected COVID-19 infection assisted at home in the Italian Province of Cremona during the pandemic’s first peak. We devised an organizational home care system which included a medical and nursing team equipped with a car for home visits, and a nurse manager who screened patient calls requesting inclusion in the project. The team administered oral drugs at home (chemotherapy, TKis, etc.) and was equipped with all necessary tools to conduct examinations, check vital signs, take blood samples, and nasopharyngeal swabs for COVID-19 testing. Results: From March 23rd to May 15th 2020, 71 cancer patients were assisted at home (181 visits, mean 2.5, SD 1.6 range 1-7). All had symptoms that could be traced back to COVID infection, but only 26/71 (37%) were found to be COVID+; 19/26 (73%) had mild symptoms, while 7 with severe symptoms were hospitalized and 2 died for COVID-19. The remaining patients recovered. 43/71 (60%) received at home oral or subcutaneous drugs and no particular problems or toxicity were observed. 16/28 (57%) of individuals living with COVID+ patients were found to be COVID+, while none of the non-cohabiting were COVID+. Conclusion: Delivery of cancer care at home is feasible and may be particularly useful not only during health crises but also after the epidemic in order to reduce hospital access, patient and care-giver travel and improve their quality of life. Further implementation studies on home-based care in oncology are warranted.
{"title":"Delivery of Cancer Care at Home during the First COVID-19 Pandemic in Italy: A Case Series Study (DomOnCOVID Project)","authors":"R. Passalacqua, M. Ratti, M. Bonomi, G. Grizzi, F. Negri, F. Crea, M. Giganti, B. Perrucci, M. Brighenti, S. Panni, M. Donini, A. Curti, D. Spada, R. Marchi, G. Donati, J. Saleri, M. Nazzari, G. Pogliacomi, F. Diodati, C. Caminiti","doi":"10.31487/j.cor.2021.06.05","DOIUrl":"https://doi.org/10.31487/j.cor.2021.06.05","url":null,"abstract":"Background: Cancer represents a major risk factor for COVID-19 poor outcomes. During the crucial phase \u0000of the pandemic, we launched a home care project, called DomOnCOVID, aiming to provide care to patients \u0000in their own homes, enabling to keep immunocompromised individuals away from health care facilities, \u0000decrease hospital use, and strengthen hospital capacity for subjects with COVID-19 and other conditions. \u0000This paper describes this intervention in terms of feasibility and clinical outcomes.\u0000Methods: This is a descriptive study of cancer patients with confirmed or suspected COVID-19 infection \u0000assisted at home in the Italian Province of Cremona during the pandemic’s first peak. We devised an \u0000organizational home care system which included a medical and nursing team equipped with a car for home \u0000visits, and a nurse manager who screened patient calls requesting inclusion in the project. The team \u0000administered oral drugs at home (chemotherapy, TKis, etc.) and was equipped with all necessary tools to \u0000conduct examinations, check vital signs, take blood samples, and nasopharyngeal swabs for COVID-19 \u0000testing. \u0000Results: From March 23rd to May 15th 2020, 71 cancer patients were assisted at home (181 visits, mean \u00002.5, SD 1.6 range 1-7). All had symptoms that could be traced back to COVID infection, but only 26/71 \u0000(37%) were found to be COVID+; 19/26 (73%) had mild symptoms, while 7 with severe symptoms were \u0000hospitalized and 2 died for COVID-19. The remaining patients recovered. 43/71 (60%) received at home \u0000oral or subcutaneous drugs and no particular problems or toxicity were observed. 16/28 (57%) of individuals \u0000living with COVID+ patients were found to be COVID+, while none of the non-cohabiting were COVID+. \u0000Conclusion: Delivery of cancer care at home is feasible and may be particularly useful not only during \u0000health crises but also after the epidemic in order to reduce hospital access, patient and care-giver travel and \u0000improve their quality of life. Further implementation studies on home-based care in oncology are warranted.\u0000","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75207319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-31DOI: 10.31487/J.COR.2021.05.08
J. Buttigieg, K. Helmerson, B. Coventry
We know that T-cell activation and effector function is integral for cancer cell destruction in immunotherapeutic treatment in oncology. The fundamental behaviour of T-cells at the time of activation is poorly understood but is likely to be central to this action. Cellular clustering occurs on at least two levels: gathering of multiple mobile cells of similar type, and aggregation between different cell types. Receptors are implicated in both of these processes. Analysis of receptor clustering is a different process whereby receptors form clusters on the cell membrane surface and can be studied to determine their relationship to immune activation. Receptor clustering has been shown to occur in some (perhaps all) cell types, but little is known about this phenomenon, particularly in T-lymphocytes. T-Cell Receptors (TCRs) which are important for the activation of T-lymphocytes. T-cell receptors, also known as cluster of differentiation 3 (CD3) molecules, bind specific antigen to create intracellular signaling in the process of T-cell activation as part of the immune response. The detail of how TCRs physically behave on the T-lymphocyte surface and specifically how they cluster remains unclear, including during the early phases of initiation of immune activation in the T-cell response. The aim of this review is to investigate how receptor clustering that has been studied, can be more effectively studied in the future and what the current evidence suggests about TCR clustering/T-cell activity relationships.
{"title":"T-Cell Receptor Clustering Methods Used for Single Cell Analysis: Potential Application in Oncology","authors":"J. Buttigieg, K. Helmerson, B. Coventry","doi":"10.31487/J.COR.2021.05.08","DOIUrl":"https://doi.org/10.31487/J.COR.2021.05.08","url":null,"abstract":"We know that T-cell activation and effector function is integral for cancer cell destruction in immunotherapeutic treatment in oncology. The fundamental behaviour of T-cells at the time of activation is poorly understood but is likely to be central to this action. Cellular clustering occurs on at least two levels: gathering of multiple mobile cells of similar type, and aggregation between different cell types. Receptors are implicated in both of these processes. Analysis of receptor clustering is a different process whereby receptors form clusters on the cell membrane surface and can be studied to determine their relationship to immune activation. Receptor clustering has been shown to occur in some (perhaps all) cell types, but little is known about this phenomenon, particularly in T-lymphocytes. T-Cell Receptors (TCRs) which are important for the activation of T-lymphocytes. T-cell receptors, also known as cluster of differentiation 3 (CD3) molecules, bind specific antigen to create intracellular signaling in the process of T-cell activation as part of the immune response. The detail of how TCRs physically behave on the T-lymphocyte surface and specifically how they cluster remains unclear, including during the early phases of initiation of immune activation in the T-cell response. The aim of this review is to investigate how receptor clustering that has been studied, can be more effectively studied in the future and what the current evidence suggests about TCR clustering/T-cell activity relationships.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82898568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：